The preparations for the market launch are in full progress; they consist of two parts: the pre-launch activities and the actual build-up of a marketing organisation.
In the course of 2007, Arpida has significantly expanded its efforts aimed at raising the awareness of iclaprim in its target audiences. Activities focus on regular contacts with opinion leaders in the field of anti-infectives, on increasing the number of publications in key journals and on securing a substantial presence at major conferences. The two main conferences coming up in the short term are ICAAC in September and IDSA in October; both take place in the USA. A total of 37 abstracts containing preclinical and clinical information on Arpidas compounds have been accepted at these conferences. Of these 37, 24 concern iclaprim with the remainder related to AR-709 and AR-2474. Arpida is working with external partners in this area to further accelerate these operations.
Both in the executive management and the Boards of Directors of both Arpida Ltd. and Arpida Inc., a wealth of expertise is present to support these activities. Dr Raths heads the European hospital-focused marketing organisation of Eli Lilly and Mr Pettigrew, MBA is Chief Operating Officer at Ferring Pharmaceuticals. Prof Bartlett, MD, who is on the Board of Arpida Inc. in the USA, is one of the leading experts in the anti-infectives field. The expertise present within Arpida should be instrumental in the build-up of the commercial organisation.
In order to provide more background to the results announcement Arpida
will host a conference call on 28 August 2007, at 3.00pm CET.
The dial-in numbers are:
The conference call (Call ID 406, followed by the #) will be available
for play-back for 48 hours by dialling:<
Copyright©2007 PR Newswire.
All rights reserved